Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash & Current Investments (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Cash & Current Investments data on record, last reported at $1.2 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 97.75% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $90.6 million, up 57.05%, while the annual FY2025 figure was $1.2 million, 97.75% down from the prior year.
  • Cash & Current Investments reached $1.2 million in Q4 2025 per FHTX's latest filing, down from $90.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $213.6 million in Q1 2022 and bottomed at $1.2 million in Q4 2025.
  • Average Cash & Current Investments over 5 years is $79.1 million, with a median of $68.4 million recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: surged 1829.97% in 2021, then crashed 97.75% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $101.1 million in 2021, then plummeted by 48.37% to $52.2 million in 2022, then surged by 53.86% to $80.3 million in 2023, then plummeted by 30.97% to $55.5 million in 2024, then plummeted by 97.75% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $1.2 million in Q4 2025, $90.6 million in Q3 2025, and $73.8 million in Q2 2025.